Project Partner

Ine Lentacker

The Ghent Research Group on Nanomedicines, headed by Prof. Stefaan De Smedt, has long-standing expertise in advanced drug delivery. Within this team, the Vaccine Delivery Group, headed by Dr. Ine Lentacker, focuses on the interface between drug delivery and immunology and aims to understand nanoparticle-immune interactions. The group has specific expertise in the formulation, physicochemical characterization, and immunological evaluation of mRNA vaccines, and they will leverage these skills to develop and test new vaccine formulations in the BAXERNA project.

Joline Ingels,
Bart Vandekerckhove &
Louise De la Mane

The Vandekerckhove lab has long-standing expertise in T cell differentiation and the development of immunotherapies. In 2016, the lab obtained a license for the production of advanced therapy medicinal products, which they have used to develop products for several clinical trials. The group is finalizing a GMP workflow for RNA lipid nanoparticle production. They will utilize this workflow as a base to develop the mRNA vaccines for the preclinical toxicity studies and phase I clinical trial in the BAXERNA project.

Isabel Leroux-Roels

The Center for Vaccinology (CEVAC), headed by Prof. Dr. Isabel Leroux-Roels, has vast experience conducting clinical vaccine studies (> 200 trials), with a focus on early development studies (phase 1 & 1/2). In addition to its clinical trial unit, the group has extensive expertise measuring vaccine-induced immune responses. In the BAXERNA project, CEVAC will set up and conduct the first-in-human, phase I clinical trial (TUBERNA) to assess the safety and immunogenicity of the candidate mRNA vaccine against M. tuberculosis.

Karim Vermaelen

The Thoracic Tumor Immunology Lab, founded by Prof. Karim Vermaelen, aims to unravel interactions between lung cancer and the immune system, with a particular focus on dendritic cells. The group has an established workflow for the collection and biobanking of human samples and a growing expertise in analysing T cell responses. In the BAXERNA project, they will assess the immunological response to the most promising vaccine candidates against M. tuberculosis in human blood samples.

Ine Lentacker

The Ghent Research Group on Nanomedicines, headed by Prof. Stefaan De Smedt, has long-standing expertise in advanced drug delivery. Within this team, the Vaccine Delivery Group, headed by Dr. Ine Lentacker, focuses on the interface between drug delivery and immunology and aims to understand nanoparticle-immune interactions. The group has specific expertise in the formulation, physicochemical characterization, and immunological evaluation of mRNA vaccines, and they will leverage these skills to develop and test new vaccine formulations in the BAXERNA project.

Joline Ingels,
Bart Vandekerckhove &
Louise De la Mane

The Vandekerckhove lab has long-standing expertise in T cell differentiation and the development of immunotherapies. In 2016, the lab obtained a license for the production of advanced therapy medicinal products, which they have used to develop products for several clinical trials. The group is currently finalizing a GMP workflow for RNA lipid nanoparticle production. They will utilize this workflow as base to develop the mRNA vaccines for the preclinical toxicity studies and phase 1 clinical trial in the BAXERNA project.

Isabel Leroux-Roels

The Center for Vaccinology (CEVAC), headed by Prof. Dr. Isabel Leroux-Roels, has vast experience conducting clinical vaccine studies (> 200 trials), with a focus on early development studies (phase 1 & 1/2). In addition to its clinical trial unit, the group has extensive expertise measuring vaccine-induced immune responses. In the BAXERNA project, CEVAC will set up and conduct the first-in-human, phase 1 clinical trial (TUBERNA) to assess the safety and immunogenicity of the candidate mRNA vaccine against M. tuberculosis.

Karim Vermaelen

The Thoracic Tumor Immunology Lab, founded by Prof. Karim Vermaelen, aims to unravel interactions between lung cancer and the immune system, with a particular focus on dendritic cells. The group has an established workflow for the collection and biobanking of human samples and a growing expertise in analysing T cell responses. In the BAXERNA project, they will assess the immunological response to the most promising vaccine candidates against M. tuberculosis in human blood samples.